Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK -Positive Non-Small Cell Lung Cancer.
Zhaohui Liao ArterMisako NagasakaPublished in: Lung Cancer (Auckland, N.Z.) (2024)
On April 18, 2024, the Food and Drug Administration approved alectinib as an adjuvant treatment for patients with anaplastic lymphoma kinase ( ALK )-positive non-small cell lung cancer (NSCLC) after tumor resection. This approval was grounded in the outcomes of the ALINA trial, which demonstrated that alectinib significantly enhances disease-free survival compared to traditional platinum-based chemotherapy in the adjuvant setting. The ALINA trial is notable not just for advancing ALK tyrosine kinase inhibitors (TKIs) into the adjuvant setting but also for its innovative approach of comparing them to adjuvant chemotherapy, distinguishing it from other landmark trials.
Keyphrases
- drug administration
- early stage
- advanced non small cell lung cancer
- phase iii
- study protocol
- free survival
- clinical trial
- phase ii
- small cell lung cancer
- open label
- randomized controlled trial
- squamous cell carcinoma
- type diabetes
- diffuse large b cell lymphoma
- metabolic syndrome
- locally advanced
- radiation therapy
- climate change
- epidermal growth factor receptor
- risk assessment
- protein kinase
- combination therapy
- replacement therapy
- double blind